Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd has announced progress in their clinical program for dengue fever treatment, revealing that new data could lead to more efficient Phase 2 clinical studies by identifying an ideal single dose for the ISLA-101 drug. This development may streamline the process, reduce costs, and expand the drug’s market potential by including a therapeutic arm. The findings are expected to de-risk the upcoming study and have been compiled for submission to the US FDA.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
